Our team

Dr. Pierre EFTEKHARI

President & Chief Scientific Officer (CSO)

Dr Eftekhari is a life sciences entrepreneur with extensive world-class knowledge in drug development. He has more than fifteen years combined academic and industrial experience in pharmacology. His considerable experience in the drug development process has equipped him to develop state-of-the-art technologies.

Prior to founding Inoviem Scientific, Dr Eftekhari co-founded two other companies offering tailored drug development services. The partnerships he has built with pharmaceutical companies and academic laboratories at the international level have given him an in-depth understanding of the pharmaceutical industry’s needs.

He holds a PhD in biology, with a major in pharmacology, from the Louis Pasteur University, Strasbourg.

Léone ATAYI

Chief Financial Officer (CFO)

Leone has been patiently involved in structuring and building up innovative companies for the passed 15 years. She has put her academic knowledge in human resource management and her practical experiences in finance and strategy making at the service of multiple companies. Before joining Inoviem scientific Leone has been working with Polyplus transfection where she acted as CFO.

Léone ATAYI

Jean-Christophe PETER

Chief Technical Officer (CTO)

Dr. Jean-Christophe Peter has over 20 years of experience in the generation of therapeutic antibodies and the diagnosis of autoimmune diseases.

He started his career in the field of G-protein coupled receptors and modulation of their activity by using antibodies. Since then, he continued to work on the antibody/antigen interaction, designed pharmacologically active antibodies and fragments thereof and established an in vivo model of autoimmune disease. After obtaining his PhD from the University of Strasbourg, he joined Prof. Hofbauer’s group at the Biozentrum of the Basel University. After two years of postdoctoral position, he was appointed associate professor in the department of applied pharmacology of the University of Basel. During this period, his work on the regulation of food intake resulted in the filing of 4 patents, the creation of OBEXIA AG in 2007 (co-founder and head of research) and he was appointed CSO in 2009. Since 2011, he was scientific manager of the center of excellence (Medalis) at Strasbourg. In 2020 he co-fund the Institute for drug discovery and development (IMS) in Strasbourg where he was appointed director of technology transfer.

Jean-Christophe Peter - CTO

Scientific Department

Dr. Leslie MULLER-SCHMITT

Head of R&D Proteomics

Lina BARRET

Assay Development Manager

Dr. Anna NIEWIADOMSKA-CIMICKA

Senior Principal Scientist

Dr. Angélique QUARTIER

Head of biology and molecular pharmacology

Dr. Judith ESCHBACH

Head of in vivo pharmacology

Camille TORLOTIN

Assay development manager

Francois LOUIS

R&D scientist/ regulatory and quality manager

Justine SCHNEIDER

Head of proteomics and analytical chemistry

Sales & Marketing Department

Pierre LABAT - Sales Director

Pierre LABAT

Head of Business Development 
(North Europe, Asia)

Alessandro BONA

Business Development Manager
(South Europe, Middle-East)

Axel VENTURINI - Sales Manager America

Axel VENTURINI

Business Development Manager
(America, Oceania)

Laura HOYEZ

Marketing Manager

Administrative Team

Jos-Claire HOUINATO

Administrative and HR Assistant

Sandrine GBATCHO

Accountant

Scientific Board

Dr. Johan HOEBEKE

Retired CNRS Research Director

Dr. Johan Hoebeke has more than 250 publications to his name in peer-reviewed international journals, as well as eight patents. His research interests focus on physical chemistry as applied to molecular immunology and molecular pharmacology. Recently retired from his position as CNRS Research Director in the Department of Immunological and Chemical Therapeutics at the Institute of Molecular and Cell Biology at the University of Strasbourg (France), Dr. Hoebeke began his career teaching at the University of Kinshasa, Democratic Republic of the Congo. Later, he joined the research laboratories at Janssen Pharmaceutical in Belgium. On his return to academic research, he worked as Senior Scientist in the Pathological Biochemistry Department of the Free University of Brussels, Belgium. He also worked at the Jacques Monod Institute in Paris and then at the François Rabelais University in Tours. He spent a sabbatical period in the Wallenberg Laboratories at the University of Gothenburg, Sweden.

Dr. Hoebeke graduated with a BSc (1959) and PhD (1965) in biochemistry from the Catholic University of Leuven, Belgium.

Professor Jörg WISCHHUSEN

Head of the Experimental Tumor Immunology Department of Würzburg University’s Medical School

Since 2013, Prof. Wishchusen has served as Head of the Experimental Tumor Immunology Department of Würzburg University’s Medical School. Currently, his research is directed towards tumor-host interactions in ovarian and breast cancer, with a strong focus on tumor-initiating cells and their ability to evade immunosurveillance. Strategies to relieve local suppression of NK and T cell effector functions by cytokines and other soluble factors are being investigated for their potential therapeutic use. Prof. Wischhusen trained as a biochemist at the University of Tübingen. After graduating in the field of molecular neuro-oncology, he became Research Group Leader at the Interdisciplinary Centre for Clinical Research in Würzburg, where he focused on mechanisms of tumor progression and immune escape.

Dr. Matthias BREIDERT

Head of the Dept. of Gastroenterology (Kantonsspital Olten, Switzerland)

Matthias Breidert, MD, assistant Professor at the Technical University of Munich, was born in 1963 in Darmstadt, Germany. Currently, head of the Dept. of Gastroenterology (Kantonsspital Olten, Switzerland). Dr. Breidert is vicepresident of the Gastroenterology Foundation e.v. (München) since 2013: support of University Hospitals for Interventional Gastroenterological Endoscopy in Nepal (Dhulikel Hospital, University Kathmandu) since 2009, Tanzania (Muhimbili Hospital, University, Daressalam) since 2010, Pristina (Kosovo) since 2019 and Bishkek (Kyrgyzstan) since 2022.

He is part of some Scientific members such as German Society of Gastroenterology and Metabolism (DGVS), Swiss Society of Gastroenterology (SGG), German Society of Endoscopy (DGE-BV),
Swiss Society for Ultrasound (SGUM, Board of Directors). 

Dr. Breidert has written more than 100 papers in peer-reviewed journals and in reviews in the field of Gastrointestinal Diseases, Endoscopy, Hepatology and Endocrinology/Diabetology, and he is main reviewer of IWQIG (The independent Institute for Quality and Efficiency in Health Care) since 2012 for Gastroenterology and Endocrinology.

Supervisory Board & Investors

Dr. Pierre EFTEKHARI

President & Chief Scientific Officer (CSO)

Dr Eftekhari is a life sciences entrepreneur with extensive world-class knowledge in drug development. He has more than fifteen years combined academic and industrial experience in pharmacology. His considerable experience in the drug development process has equipped him to develop state-of-the-art technologies.

Prior to founding Inoviem Scientific, Dr Eftekhari co-founded two other companies offering tailored drug development services. The partnerships he has built with pharmaceutical companies and academic laboratories at the international level have given him an in-depth understanding of the pharmaceutical industry’s needs.

He holds a PhD in biology, with a major in pharmacology, from the Louis Pasteur University, Strasbourg.

Léone ATAYI

Chief Financial Officer (CFO)

Leone has been patiently involved in structuring and building up innovative companies for the passed 15 years. She has put her academic knowledge in human resource management and her practical experiences in finance and strategy making at the service of multiple companies. Before joining Inoviem scientific Leone has been working with Polyplus transfection where she acted as CFO.

Jean-Paul ANSEL

Board Member

Jean-Paul has more than 45 years of international banking and financing experience. His academic knowledge is rooted in Paris business school (ESCP) that allows him to grow his highly riche international experience through  Scoa, Davum, MITSUI, Bank worms group, The Chase Manhattan bank N.A, Merill Lynch, HSBC Investment Bank, Commerzbank securities and Pennel Industries.

Jean-Paul is leading DMS group where his expertise has blossomed through acquirement of  several companies all highly focused on human health, particularly personalized medicine. 

Need Help